OptimizeRx CorporationOPRXNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank100
5Y CAGR+58.6%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

5Y CAGR
+58.6%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
10x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM14.98%+255.1%
2024-9.66%+67.6%
2023-29.79%-97.6%
2022-15.08%-497.3%
20213.80%+154.1%
20201.49%+124.3%
2019-6.14%-205.3%
20185.83%+139.2%
2017-14.89%+11.5%
2016-16.82%-